Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.42 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2090993 | 0.82 | NFE2L2 (0.47) | MEN1KMT2ACSNK2A1SMN1; SMN2ALDH1A1 | |
| SCHEMBL9862051 | 0.81 | MEN1 (0.57) | MEN1KMT2ACSNK2A1TSHRSMN1; SMN2 | |
| SCHEMBL9420245 | 0.81 | MEN1 (0.57) | MEN1KMT2ACSNK2A1TSHRSMN1; SMN2 | |
| SCHEMBL29636568 | 0.79 | KMT2A (0.55) | MEN1KMT2ACSNK2A1TSHRSMN1; SMN2 | |
| SCHEMBL697905 | 0.79 | KMT2A (0.55) | MEN1KMT2ACSNK2A1TSHRSMN1; SMN2 | |
| SCHEMBL223101 | 0.79 | CSNK2A1 (0.65) | MEN1KMT2ACSNK2A1TSHRSMN1; SMN2 | |
| SCHEMBL501733 | 0.79 | MEN1 (0.55) | MEN1KMT2ACSNK2A1TSHRSMN1; SMN2 | |
| SCHEMBL10389402 | 0.78 | MEN1 (0.50) | MEN1KMT2ACSNK2A1TSHRSMN1; SMN2 | |
| SCHEMBL7113261 | 0.78 | MEN1 (0.50) | MEN1KMT2ACSNK2A1TSHRSMN1; SMN2 | |
| SCHEMBL18568450 | 0.78 | MEN1 (0.53) | MEN1KMT2ACSNK2A1TSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9714560-B2 | Protected scale inhibitors and methods relating thereto | HALLIBURTON ENERGY SERVICES, INC. (US) | 2017-07-25 | — | — | US | claimed |
| CN-117986153-A | Ionizable cationic lipid compound, and preparation method and application thereof | 晟迪生物医药(苏州)有限公司 | 2024-05-07 | — | — | CN | disclosed |
| US-20220153932-A1 | PREPOLYMERS OF 1,1-DICARBONYL SUBSTITUTED-1-ALKENE, METHODS TO MAKE THEM, POLYMERS MADE FROM THEM AND METHODS TO MAKE THE POLYMER | SIRRUS INC (US) | 2022-05-19 | — | — | US | disclosed |
| US-20220112151-A1 | COMPOSITIONS OF DICARBONYL SUBSTITUTED-1-ALKENE, METHODS TO MAKE THEM, POLYMERS MADE FROM THEM AND METHODS TO MAKE THE POLYMER | SIRRUS INC (US) | 2022-04-14 | — | — | US | disclosed |
| US-11198757-B2 | Compositions including a photolatent amine, camphorquinone, and coumarin and related methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2021-12-14 | — | — | US | disclosed |
| US-20210371667-A1 | COMPOSITION INCLUDING AMINO-FUNCTIONAL SILANES AND METHOD OF APPLYING A SEALANT TO A SUBSTRATE | 3M INNOVATIVE PROPERTIES COMPANY | 2021-12-02 | — | — | US | disclosed |
| WO-2021231288-A1 | IMPROVED DICARBONYL SUBSTITUTED-1-ALKENE COMPOSITIONS | NIPPON SHOKUBAI CO., LTD. (JP) | 2021-11-18 | — | — | WO | disclosed |
| US-11090681-B2 | Composition including a polythiol, a polyepoxide, a photolatent base, and an amine and methods relating to the composition | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2021-08-17 | — | — | US | disclosed |
| EP-3856849-A1 | COMPOSITION INCLUDING AMINO-FUNCTIONAL SILANES AND METHOD OF APPLYING A SEALANT TO A SUBSTRATE | 3M Innovative Properties Company (US) | 2021-08-04 | — | — | EP | disclosed |
| WO-2021150844-A1 | COMPOSITIONS CONTAINING 1,1-DISUBSTITUTED ACTIVATED ALKENES USEFUL IN ADDITIVE MANUFACTURING AND ARTICLES FORMED THEREFROM | SIRRUS, INC. (US) | 2021-07-29 | — | — | WO | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | MEN1 3295/4885KMT2A 4267/4885CSNK2A1 1171/4885 |
| US-20220112151-A1 | COMPOSITIONS OF DICARBONYL SUBSTITUTED-1-ALKENE, METHODS TO MAKE THEM, POLYMERS MADE FROM THEM AND METHODS TO MAKE THE POLYMER | PARG, PARN, LIG1 | MEN1 1628/4885KMT2A 2305/4885CSNK2A1 3915/4885 |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | MEN1 4525/4885KMT2A 3324/4885CSNK2A1 967/4885 |
| US-20220153932-A1 | PREPOLYMERS OF 1,1-DICARBONYL SUBSTITUTED-1-ALKENE, METHODS TO MAKE THEM, POLYMERS MADE FROM THEM AND METHODS TO MAKE THE POLYMER | PLOD1, COL1A1, PLOD2 | MEN1 1555/4885KMT2A 2902/4885CSNK2A1 4400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.